Open-label Study of Surufatinib in Japanese Patients
Status:
Recruiting
Trial end date:
2024-05-10
Target enrollment:
Participant gender:
Summary
This is a phase 1/2, open-label, multi-centre study of surufatinib in patients with
unresectable, locally advanced, or recurrent nonhematologic malignancies who do not respond
or are intolerant to standard of care.